Compare SRPT & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRPT | SAM |
|---|---|---|
| Founded | 1980 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2000 | 1996 |
| Metric | SRPT | SAM |
|---|---|---|
| Price | $17.12 | $183.81 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 29 | 11 |
| Target Price | $25.85 | ★ $233.70 |
| AVG Volume (30 Days) | ★ 2.7M | 254.4K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 95.45 |
| EPS | ★ 2.88 | N/A |
| Revenue | ★ $2,198,237,000.00 | $1,964,994,000.00 |
| Revenue This Year | N/A | $1.02 |
| Revenue Next Year | N/A | $1.31 |
| P/E Ratio | $5.78 | ★ N/A |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $10.42 | $169.98 |
| 52 Week High | $43.92 | $264.46 |
| Indicator | SRPT | SAM |
|---|---|---|
| Relative Strength Index (RSI) | 34.11 | 31.39 |
| Support Level | $16.09 | N/A |
| Resistance Level | $19.32 | $229.36 |
| Average True Range (ATR) | 1.14 | 8.70 |
| MACD | -0.48 | -2.18 |
| Stochastic Oscillator | 8.24 | 26.16 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.